pharma · sickle cell anaemia · Chronic Obstructive Pulmonary Disease
Pierre Fabre Medical
Pierre Fabre Australia Pty Ltd
Pierre Fabre Australia is a pharma organization headquartered in AU. Primary therapeutic focus areas include sickle cell anaemia, Chronic Obstructive Pulmonary Disease. NovaPharmaNews links 3 clinical program(s), 2 drug
North Sydney, AU HQ
2002 Founded
5 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- North Sydney, AU
- Founded
- 2002
- Employees
- 5
- Programs
- 3
- Drugs
- 18
- Patents
- 0
LIDOCAINE HYDROCHLORIDE, MORPHINE HYDROCHLORIDE
Approved · small molecule · sickle cell anaemia
LIDOCAINE HYDROCHLORIDE, MORPHINE HYDROCHLORIDE for sickle cell anaemia is a Approved program (small_molecule) at Pierre Fabre Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pierre Fabre Australia Pty Ltd
- Phase
- Approved
- Modality
- small_molecule
- Indication
- sickle cell anaemia
- Status
- active
- Trials
- 1